University of Utah

Amylyx Hopes Sunnybrook Might Discover New Methods For Fighting ALS Although it is in the midst of a protracted effort to obtain US Food and Drug Administration approval for its investigational mitoch

Atavistik Bio revealed a $60m series A round on 24 August that it will use to ramp up its discovery of novel therapeutics with distinct allosteric control mechanisms for the treatment of metabolic di

Based on its founder’s graduate work at the University of Utah , Recursion Pharmaceuticals LLC is repurposing existing molecules for rare monogenic diseases by using phenotypic screening that is op

Genentech Inc. is taking another stab at the pain market, signing on very early to Kineta Chronic Pain LLC 's nicotinic acetylcholine receptor alpha 9/10 antagonist program. The biotech thinks it ma